TsiporahBShoreMD

Hematologic Oncology

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Shore

Dr. Tsiporah Shore is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including NewYork-Presbyterian/Weill Cornell and New York-Presbyterian Hospital. She received her medical degree from University of Manitoba and has been in practice 38 years. She specializes in hematologic oncology and is experienced in hematologic oncology, and bone marrow/ stem cell transplantation.

Office
520 E 70th St # Starr-341
New York, NY 10021
Book by Phone+1(804) 451-3430

Fax+1 212-746-0701

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1985
University of ManitobaClass of 1979

Certifications & Licensure

NY State Medical License 1999 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Royal College of Physicians and Surgeons of CanadaHematology
Royal College of Physicians and Surgeons of CanadaInternal Medicine

Awards, Honors, & Recognition

Certificate of Excellence in Reviewing Leukemia Research, 2013
Fellow American College of Physicians, 1999
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
Research Tissue Bank Start of enrollment: 2007 Sep 01
Completed
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma Start of enrollment: 2009 Apr 23
Completed
Phase 1, Phase 2
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Start of enrollment: 2009 Jul 01
Completed
Phase 1
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Contact, Principal Investigator
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma Start of enrollment: 2012 Mar 01
Active, not recruiting
Phase 2
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Completed
Phase 3
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis Start of enrollment: 2013 Nov 01
Terminated
Phase 2
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Start of enrollment: 2013 Aug 01
Completed
Phase 3
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma Start of enrollment: 2014 Jun 04
Completed
Phase 1, Phase 2
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
Roles: Contact
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2021 Mar 29
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).
Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, Marie Liu, Sebastian A Mayer
Transplantation and Cellular Therapy. 2024-11-01
Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomes.
Koen van Besien, Hongtao Liu, Seunghee Margevicius, Pingfu Fu, Andrew Artz
Leukemia & Lymphoma. 2024-10-01
1 citations
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
Samuel Yamshon, Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen
Clinical Lymphoma, Myeloma & Leukemia. 2024-06-01

Journal Articles

Incidence, Significance, and Persistence of Human Coronavirus Infection in Hematopoietic Stem Cell Transplant Recipients
Catherine B Small, Rosemary Soave, Dana Zappetti, Michael J Satlin, Emily M Eichenberger, Tsiporah Shore, Nature

Abstracts/Posters

Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34+ pr...
Tsiporah B. Shore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Thirty-Day Transfusion and G-CSF Requirement after CD19 CAR T Infusion
Tsiporah B. Shore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Haplo-Cord Transplantation with Anti-Thymocyte Globulin: Comparative Clinical Outcomes with or without Routine G-CSF Administration
Tsiporah B. Shore, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019

Lectures

CCR5 delta32 Cord & Haploidentical Grafts: Allogeneic Stem Cell Transplant for HIV+ /AML Patient: A Case Report from the Impaact P1107 Observational StudyClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Idaho PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
PacificSource Preferred PSN
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment